Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Simon Lichtiger

Internal Medicine New York, NY Medical Doctor

NPI 1053409847 CMS profile 319866

12 E 86Th St, Ste 1, New York, NY 10028

Open in the dashboard

General payments

$242,858

160 records reported · program years 2019–2024

Research payments

$3,519

Paid to them · 1 record reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$923,226 paid to institutions, not to them · program years 2019–2022

Through program year 2024, Simon Lichtiger of New York, NY is reported in the CMS Open Payments database as having received $242,858 across 160 general payments and $3,519 in research payments paid to them. Separately, studies naming them as principal investigator received $923,226 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $37,902 1
2021 General $31,522 26
2021 Research $3,519 1
2020 General $39,920 28
2019 General $133,515 105

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Simon Lichtiger
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Simon Lichtiger were reported at $0. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Simon Lichtiger Internal Medicine median Middle half National median
2019 $133,515 $159 $48–$570 $163
2020 $39,920 $119 $33–$402 $114
2021 $31,522 $135 $37–$521 $132
2022 $0 $141 $42–$496 $149
2023 $0 $149 $45–$519 $160
2024 $37,902 $154 $47–$537 $164
2025 $0 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. AbbVie, Inc. $187,212 118 payments
  2. Janssen Scientific Affairs, LLC $27,897 18 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $19,103 10 payments
  4. Janssen Biotech, Inc. $8,603 12 payments
  5. Salix Pharmaceuticals, a division of Bausch Health US, LLC $23 1 payment
  6. Romark Laboratories, LC $21 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $170,825 62 payments
  2. Acquisitions $37,902 1 payment
  3. Travel and Lodging $24,270 46 payments
  4. Consulting Fee $7,000 1 payment
  5. Food and Beverage $2,832 46 payments
  6. Education $29 4 payments
Products named General payments · program years 2019–2024
  1. HUMIRA $108,208 82 payments
  2. STELARA $36,500 30 payments
  3. Entyvio Lower GI $18,990 9 payments
  4. ENTYVIO Internal Medicine $112 1 payment
  5. SIMPONI $78 3 payments
  6. XIFAXAN $23 1 payment
  7. ALINIA Gastroenterology $21 1 payment
  8. ALINIA Gastroenterology $21 1 payment
  9. ALINIA Gastroenterology $21 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. Eli Lilly and Company $3,519 1 payment

Records

161 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record